Table 4.
Changes in fasting lipids from baseline to week 96
| Metabolic assessment | Study 1216 | Study 1160 | ||||
|---|---|---|---|---|---|---|
| RPV/FTC/TAF (n = 316) | RPV/FTC/TDF (n = 314) | P‐value | RPV/FTC/TAF (n = 438) | EFV/FTC/TDF (n = 437) | P‐value | |
| Total cholesterol (mg/dL) | ||||||
| Baseline | 173 (152, 196) | 167 (152, 188) | 0.07 | 191 (170, 211) | 192 (167, 215) | 0.88 |
| Change at week 96 | 19 (4, 34) | 3 (−12, 18) | < 0.001 | −13 (−32, 10) | −3 (−19, 15) | < 0.001 |
| Direct LDL cholesterol (mg/dL) | ||||||
| Baseline | 109 (89, 129) | 105 (89, 123) | 0.12 | 115 (97, 135) | 117 (97, 139) | 0.46 |
| Change at week 96 | 15 (2, 28) | 3 (−9, 15) | < 0.001 | −2 (−20, 14) | 0 (−13, 13) | 0.22 |
| HDL cholesterol (mg/dL) | ||||||
| Baseline | 47 (39, 56) | 46 (38, 55) | 0.34 | 52 (43, 65) | 53 (44, 63) | 0.99 |
| Change at week 96 | 2 (−2, 8) | 0 (−5, 6) | 0.006 | −4 (−11, 1) | 0 (−6, 6) | < 0.001 |
| Triglycerides (mg/dL) | ||||||
| Baseline | 101 (74, 147) | 100 (72, 148) | 0.47 | 116 (83, 175) | 116 (79, 170) | 0.36 |
| Change at week 96 | 16 (−14, 53) | 3 (−27, 35) | < 0.001 | 1 (−34, 24) | 4 (−25, 35) | 0.14 |
| Total to HDL cholesterol ratio | ||||||
| Baseline | 3.6 (2.9, 4.5) | 3.5 (2.9, 4.5) | 0.60 | 3.6 (2.9, 4.3) | 3.5 (2.9, 4.4) | 0.95 |
| Change at week 96 | 0.2 (−0.3, 0.5) | 0 (−0.4, 0.5) | 0.03 | 0.1 (−0.4, 0.5) | 0 (−0.5, 0.4) | 0.06 |
Values are median (IQR). P‐values are from the two‐sided Wilcoxon rank sum test to compare the two treatment groups.
HDL, high‐density lipoprotein; IQR, interquartile range; LDL, low‐density lipoprotein; EFV, efavirenz; FTC, emtricitabine; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.